NASDAQ · Medical - Diagnostics & Research

MDxHealth S.A. (MDXH) Stock

$0.42 +1.51% NASDAQ: MDXH Healthcare

MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union.

Valuation

MetricValue
Price$0.42
Market Cap$21.38M
P/E Ratio-0.61
P/B Ratio-1.70
P/S Ratio0.26
EPS (TTM)$-0.67
52-Week High$5.33
52-Week Low$0.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE402.97%
ROA-17.67%
ROCE-13.70%
Gross Margin-13.89%
Operating Margin-13.89%
Net Margin-32.17%
Debt/Equity-7.86
Current Ratio1.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$22.0M$37.0M$70.0M$90.0M$108.0M
Operating Profit$-27.0M$-38.0M$-27.0M$-25.0M$-15.0M
Net Profit$-29.0M$-44.0M$-43.0M$-38.0M$-34.0M
EPS$-2.38$-2.78$-1.66$-1.16$-0.67
Op Margin-120.7%-102.3%-38.9%-27.4%-14.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$75.0M$119.0M$129.0M$157.0M$148.0M
Total Liabilities$28.0M$110.0M$122.0M$142.0M$160.0M
Cash$58.0M$16.0M$22.0M$47.0M$29.0M
Borrowings$16.0M$40.0M$41.0M$60.0M$95.0M

Latest News

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13 GlobeNewswire · Jul 30, 2026 Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency GlobeNewswire · Jul 24, 2026 MDxHealth Gets Nasdaq Non-Compliance Notice MT Newswires · Jul 2, 2026 Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency GlobeNewswire · Jul 2, 2026 Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-23.0M$-34.0M$-21.0M$-19.0M$-10.0M
Investing Cash Flow$-2.0M$-33.0M$-9.0M$-4.0M$-21.0M
Financing Cash Flow$-1.0M$-1.0M$-4.0M$-8.0M$-9.0M
Net Cash Flow$43.0M$-43.0M$7.0M$24.0M$-18.0M
Free Cash Flow$-23.0M$-38.0M$-27.0M$-21.0M$-12.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-14.67
FCF Yield-56.13%
Quick Ratio0.92
Interest Coverage-1.25
Return 1Y-79.86%
Return 3Y-87.60%
Return 5Y—

Ownership

Insiders Held11.13%
Institutions Held38.04%
Institutions Float Held42.81%
Institutional HolderSharesReport Date
Bleichroeder LP7,378,3332026-03-31
AWM Investment Company, Inc.5,221,2822026-03-31
MVM Partners, LLC4,700,4572026-03-31
Samjo Management, LLC1,449,4502026-03-31
Perkins Capital Management, Inc.1,411,8912026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRS $5.91 -2.96% -6.68 $825.41M 0.00%
ASMB $26.68 +0.87% -51.53 $424.02M 0.00%
IMRX $4.24 -2.75% -3.94 $153.92M 0.00%
NEO $13.14 -5.40% -1.96 $342.20M 0.00%
QTRX $3.38 -3.15% -1.00 $159.22M 0.00%

About MDxHealth S.A.

MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.

MDxHealth S.A. is led by CEO Michael K. McGarrity, employs 312 people, headquartered in BE, publicly traded since 2021.

MDxHealth S.A. (MDXH) stock trades at $0.42 with a market capitalization of $21.38M. The stock is valued at a price-to-earnings (P/E) ratio of -0.61, price-to-book of -1.70, price-to-sales of 0.26. Over the past 52 weeks the stock has ranged between $0.40 and $5.33, and currently trades 92.1% below its 52-week high.

On profitability, MDxHealth S.A. generates a return on equity (ROE) of 402.97% — well above the market average, a sign of a high-quality business, return on capital employed of -13.70%, an operating margin of -13.89%, a net profit margin of -32.17%.

Official website: mdxhealth.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides